. Author manuscript; available in PMC: 2015 Oct 15.

Published in final edited form as: Clin Cancer Res. 2015 Feb 3;21(8):1869–1876. doi: 10.1158/1078-0432.CCR-14-2424

Table 4. Incidence and risk of infection between different inhibitors of PI3K-AKT-mTOR pathway.

	All grade infection				Grade 3/4 infection
	No	Yes	OR (95% CI)	p	No	Yes	OR (95% CI)	p
Controls	92 (92%)	8 (8%)	-	-	98 (98%)	2 (2%)	-	-
mTORCi	105 (74.5%)	36 (25.5%)	3.9 (1.7-8.9)	0.001	128 (90.7%)	13 (9.3%)	4.9 (1.0-22.5)	0.03
PI3Ki	62 (79.5%)	16 (20.5%)	2.9 (1.1-7.3)	0.019	70 (89.7%)	8 (10.3%)	5.6 (1.1-27.1)	0.03
Multi kinase PI3K/mTORC inhibitors	15 (36.6%)	26 (63.4%)	19.9 (7.6-52.1)	<0.0001	30 (73.2%)	11(26.8%)	17.9 (3.7-85.6)	0.0003
AKTi	85 (80.2%)	21 (19.8%)	2.8 (1.1-6.7)	0.018	100 (94.4%)	6 (5.6%)	2.9 (0.5-14.9)	0.19